Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2611001rdf:typepubmed:Citationlld:pubmed
pubmed-article:2611001lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:2611001lifeskim:mentionsumls-concept:C0006684lld:lifeskim
pubmed-article:2611001lifeskim:mentionsumls-concept:C0596901lld:lifeskim
pubmed-article:2611001lifeskim:mentionsumls-concept:C0442034lld:lifeskim
pubmed-article:2611001lifeskim:mentionsumls-concept:C0042523lld:lifeskim
pubmed-article:2611001lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:2611001lifeskim:mentionsumls-concept:C0031164lld:lifeskim
pubmed-article:2611001lifeskim:mentionsumls-concept:C0031140lld:lifeskim
pubmed-article:2611001pubmed:issue6lld:pubmed
pubmed-article:2611001pubmed:dateCreated1990-3-14lld:pubmed
pubmed-article:2611001pubmed:abstractTextPeritoneal clearances of small solutes, mass transfer, ultrafiltration, and the mass transfer area coefficient were measured in order to evaluate the effect of calcium antagonists on the permeability of the peritoneal membrane in patients on continuous ambulatory peritoneal dialysis. We studied 10 patients before and after the instillation of 10 mg (5 mg/l) of verapamil into the peritoneal cavity. Our results showed a significant increase of urea, creatinine, and uric acid clearances. A significant increase in ultrafiltration and mass transfer coefficient area was also observed (p less than 0.05), while the mass transfer of K+, Na+, and Ca2+ was essentially unchanged. These findings indicate that the intraperitoneal use of verapamil may induce an increase in the peritoneal permeability in patients on continuous ambulatory peritoneal dialysis.lld:pubmed
pubmed-article:2611001pubmed:languageenglld:pubmed
pubmed-article:2611001pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2611001pubmed:citationSubsetIMlld:pubmed
pubmed-article:2611001pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2611001pubmed:statusMEDLINElld:pubmed
pubmed-article:2611001pubmed:issn0253-5068lld:pubmed
pubmed-article:2611001pubmed:authorpubmed-author:VargemezisVVlld:pubmed
pubmed-article:2611001pubmed:authorpubmed-author:PasadakisPPlld:pubmed
pubmed-article:2611001pubmed:authorpubmed-author:ThodisEElld:pubmed
pubmed-article:2611001pubmed:issnTypePrintlld:pubmed
pubmed-article:2611001pubmed:volume7lld:pubmed
pubmed-article:2611001pubmed:ownerNLMlld:pubmed
pubmed-article:2611001pubmed:authorsCompleteYlld:pubmed
pubmed-article:2611001pubmed:pagination309-13lld:pubmed
pubmed-article:2611001pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:2611001pubmed:meshHeadingpubmed-meshheading:2611001-...lld:pubmed
pubmed-article:2611001pubmed:meshHeadingpubmed-meshheading:2611001-...lld:pubmed
pubmed-article:2611001pubmed:meshHeadingpubmed-meshheading:2611001-...lld:pubmed
pubmed-article:2611001pubmed:meshHeadingpubmed-meshheading:2611001-...lld:pubmed
pubmed-article:2611001pubmed:meshHeadingpubmed-meshheading:2611001-...lld:pubmed
pubmed-article:2611001pubmed:meshHeadingpubmed-meshheading:2611001-...lld:pubmed
pubmed-article:2611001pubmed:meshHeadingpubmed-meshheading:2611001-...lld:pubmed
pubmed-article:2611001pubmed:meshHeadingpubmed-meshheading:2611001-...lld:pubmed
pubmed-article:2611001pubmed:meshHeadingpubmed-meshheading:2611001-...lld:pubmed
pubmed-article:2611001pubmed:meshHeadingpubmed-meshheading:2611001-...lld:pubmed
pubmed-article:2611001pubmed:meshHeadingpubmed-meshheading:2611001-...lld:pubmed
pubmed-article:2611001pubmed:year1989lld:pubmed
pubmed-article:2611001pubmed:articleTitleEffect of a calcium antagonist (verapamil) on the permeability of the peritoneal membrane in patients on continuous ambulatory peritoneal dialysis.lld:pubmed
pubmed-article:2611001pubmed:affiliationDemocritus University of Thrace, Division of Nephrology, General District Hospital, Alexandroupolis, Greece.lld:pubmed
pubmed-article:2611001pubmed:publicationTypeJournal Articlelld:pubmed